menu

Should EPA Be Another 'E' in the ABCs of CVD Risk Prevention? Straight Talk from the Experts

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Should EPA Be Another 'E' in the ABCs of CVD Risk Prevention? Straight Talk from the Experts

close
0.50 credits
30 minutes
Should EPA Be Another 'E' in the ABCs of CVD Risk Prevention? Straight Talk from the Experts
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    This activity is presented by outstanding educators in the field of lipidology and preventive cardiology. Join Drs. Erin D. Michos, James A. Underberg, and Nathan D. Wong for a deep dive into these hot topics: new pathways to manage high risk in ASCVD, differential biological effects of omega-3 fatty acids, and practical considerations to manage ASCVD risk. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Faculty:

    Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC
    Director of Women’s Cardiovascular Health
    Associate Director of Preventive Cardiology
    Associate Professor of Medicine and Epidemiology
    Ciccarone Center for the Prevention of Cardiovascular Disease
    Division of Cardiology
    Johns Hopkins School of Medicine
    Baltimore, MD

    No relationships reported.

    James A. Underberg, MD, MS
    Clinical Lipidology
    Clinical Assistant Professor of Medicine
    NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease
    Director, Bellevue Hospital Lipid Clinic
    President, National Lipid Association
    New York, NY

    Consulting Fees:  Amgen, Esperion, Novartis
    Speakers Bureau: Alexion, Amarin, Amgen, Amryt Pharma, Esperion
    Contracted Research: Amryt Pharma

    Nathan D. Wong, PhD, FACC, FAHA, FNLA, FASPC
    Past President, American Society for Preventive Cardiology
    Professor and Director
    Heart Disease Prevention Program
    Division of Cardiology
    University of California, Irvine School of Medicine
    Irvine, CA

    Contracted Research: Amarin, Amgen, Esperion, Novartis
    Consulting Fees: Novartis
    Speaker Bureau: Amarin, Esperion

    Reviewers/Content Planners/Authors:

    • Ben Caref, PhD, has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Milly Marte has nothing to disclose.
    • Erin Michos has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Have greater competence on risk stratifying patients for potential ASCVD events
    • Describe the impact of recent randomized cardiovascular outcomes trials to reduce ASCVD risk
    • Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
    • Apply evidence-based guidelines, recent trial evidence, and cost utility of ASCVD therapy in practice
  • Target Audience

    This activity is designed to meet the educational needs of internists, primary care physicians, hospitalists, and allied healthcare professionals, including pharmacists, nurse practitioners, physician assistants, dietitians, and nurses.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    This activity is presented by outstanding educators in the field of lipidology and preventive cardiology. Join Drs. Erin D. Michos, James A. Underberg, and Nathan D. Wong for a deep dive into these hot topics: new pathways to manage high risk in ASCVD, differential biological effects of omega-3 fatty acids, and practical considerations to manage ASCVD risk. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Faculty:

    Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC
    Director of Women’s Cardiovascular Health
    Associate Director of Preventive Cardiology
    Associate Professor of Medicine and Epidemiology
    Ciccarone Center for the Prevention of Cardiovascular Disease
    Division of Cardiology
    Johns Hopkins School of Medicine
    Baltimore, MD

    No relationships reported.

    James A. Underberg, MD, MS
    Clinical Lipidology
    Clinical Assistant Professor of Medicine
    NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease
    Director, Bellevue Hospital Lipid Clinic
    President, National Lipid Association
    New York, NY

    Consulting Fees:  Amgen, Esperion, Novartis
    Speakers Bureau: Alexion, Amarin, Amgen, Amryt Pharma, Esperion
    Contracted Research: Amryt Pharma

    Nathan D. Wong, PhD, FACC, FAHA, FNLA, FASPC
    Past President, American Society for Preventive Cardiology
    Professor and Director
    Heart Disease Prevention Program
    Division of Cardiology
    University of California, Irvine School of Medicine
    Irvine, CA

    Contracted Research: Amarin, Amgen, Esperion, Novartis
    Consulting Fees: Novartis
    Speaker Bureau: Amarin, Esperion

    Reviewers/Content Planners/Authors:

    • Ben Caref, PhD, has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Milly Marte has nothing to disclose.
    • Erin Michos has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Have greater competence on risk stratifying patients for potential ASCVD events
    • Describe the impact of recent randomized cardiovascular outcomes trials to reduce ASCVD risk
    • Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
    • Apply evidence-based guidelines, recent trial evidence, and cost utility of ASCVD therapy in practice
  • Target Audience

    This activity is designed to meet the educational needs of internists, primary care physicians, hospitalists, and allied healthcare professionals, including pharmacists, nurse practitioners, physician assistants, dietitians, and nurses.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 6/13/21